CDR2

Across TCGA pan-cancer cohorts, CDR2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CDR2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where CDR2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CDR2 is over-expressed in tumor, although a few such as LSCC and CCRCC show the opposite, repressed pattern.

COAD, LUAD, and HNSC are the cancer types where CDR2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDR2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	All	+0.521	.001	9	view →
LUAD	All	III,IV	+0.217	<.001	9	view →
HNSC	Male	All	+0.352	<.001	6	view →
LSCC	Male	III,IV	−0.170	.016	3	view →
CCRCC	Male	All	−0.117	.010	2	view →
PDAC	Female	All	+0.166	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CDR2–COAD

Open the COAD breakdown →